Join Us at ATS | Insilico Medicine Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Led by Alex Zhavoronkov, Ph.D, founder and co-CEO of Insilico Medicine, Sujata Rao, M.D, Chief Medical Officer, Michelle Chen, Ph.D, Chief Business Officer, and Carol Satler, M.D, PhD, SVP of Clinical Development, the experienced Insilico team will be welcoming collaboration and clinical insight conversations at Booth #1464, Halls ABC Moscone Center.
All presentations will focus on exploring the potential of rentosertib (INS018_055), a novel TNIK inhibitor developed using Insilico's generative AI approach, for the treatment of idiopathic pulmonary fibrosis (IPF). Previously, Insilico received encouraging results from a Phase IIa study of rentosertib, demonstrating its safety, tolerability, favorable pharmacokinetic profile, and preliminary clinical efficacy as measured by improvement in forced vital capacity (FVC) at 12 weeks. Notably, the study, for the first time, validated the biological mechanism of treating IPF by targeting TNIK—a novel target identified through generative AI—in a clinical setting, and presented the proof-of-concept validation of AI-driven drug discovery and development.
The following abstracts are posted on ATS 2025’s online itinerary planner for registered users:
Oral Presentation: Generative AI & The Future of Drug Development: A New Era of AI Designed IPF Drug Therapy Presenter: Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine Session: Respiratory Innovation Summit Date and time: Saturday, May 17, 11:30 a.m. – 12:00 p.m. PT
Poster Presentation: Insilico Medicine: End-to-end generative AI-driven drug discovery and development Session: Respiratory Innovation Summit Date and time: Friday, May 16, 5:00 p.m. – 9:00 p.m. PT ; Saturday, May 17, 7:15 a.m. – 6:00 p.m. PT
Poster Presentation: An ASCENT to Week 8: INS018-055, A Novel Traf2- and NCK-interacting Kinase (TNIK) Inhibitor, Improves Lung Function in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2a Study
Session A101: New Approaches To The Monitoring And Treatment of ILD Poster: 8657 Date and time: Sunday, May 18, 2:15 p.m. – 4:15 p.m. PT
Poster Presentation: Biomarker Analysis Reveals Antifibrotic and Anti-inflammatory Signatures in Idiopathic Pulmonary Fibrosis Patients Treated With INS018_055, an AI-discovered TNIK Inhibitor, in a 12- week Phase 2a (Late Breaker)
Session C23: On The Horizon: Imaging And Molecular Biomarkers In Fibrotic ILD Poster: 5115 Date and time: Tuesday, May 20, 9:15 a.m. – 11:15 a.m. PT
By integrating cutting-edge AI and automation technologies, Insilico Medicine has achieved significant efficiency gains compared to traditional drug discovery methods, which typically take 2.5–4 years. As announced in recent key timeline benchmarks for its 22 internal drug candidate programs from 2021 to 2024, Insilico has demonstrated remarkable performance, with an average timeline to DC of just 12–18 months, 60–200 molecules synthesized and tested per program, and a 100% success rate in advancing from DC to the IND-enabling stage.